阿立哌唑治疗精神分裂症临床观察

目的：探讨阿立哌唑治疗精神分裂症的疗效与安全。方法：111例精神分裂症患者随机分为两组,阿立哌唑组56例,氯氮平组55例,于治疗1、2、4、6、8周末进行阳性与阴性症状量表（PANSS）、副反应量表（TESS）评定疗效及不良反应。结果：阿立哌唑与氯氮平总疗效比较,差异无统计学意义（P〉0.05）;在认知因子和阴性症状方面,以阿立哌唑疗效显著。阿立哌唑的主要不良反应明显低于氯氮平。结论：阿立哌唑是一种安全、有效的非典型抗精神病药。

Clinical observation of Aripiprazole in the treatment of schizophrenia

Objective：To explore the efficacy and safety of Aripiprazole in the treatment of schizophrenia. Methods：111 cases of patients with schizophrenia were randomly divided into Aripiprazole group （n=56） and Clozapine group （n=55）. Positive and negative symptoms scale （PANSS） and treatment emergent symptom scale （TESS） were used to measure the efficacy and safety before treatment and treatment at the end of 1st,2nd,4th,6th and 8th week respectively. Results：There was no significant difference in efficacy between two groups （P0.05）. However,significant differences were observed between two groups in the reduction rates of scales about cognitive factors and negative symptoms. Conclusion：Aripiprazole is a safe and effective agent in the treatment of schizophrenia.